CYP2D6Genetic Polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas

References

• Silva-Zolezzi I , Hidalgo-MirandaA , Estrada-GilJet al. Analysis of genomic diversity in Mexican Mestizo populations to develop genomic medicine in Mexico . Proc. Natl Acad. Sci. USA106 ( 21 ), 8611 – 8616 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Zanger UM , RaimundoS , EichelbaumM . Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry . Naunyn Schmiedebergs Arch. Pharmacol.369 ( 1 ), 23 – 37 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Dorado P , Suarez-KurtzG , LLerenaA . Pharmacogenetics of cytochrome P450 in Hispanic populations . In : Pharmacogenomics in Admixed Populations.Suarez-KurtzG ( Ed. ). Landes Bioscience , Austin , 60 – 74 ( 2007 ).
   Google Scholar
• LLerena A , CobaledaJ , MartínezC , BenítezJ . Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype . Eur. J. Drug. Metab. Pharmacokinet.21 ( 2 ), 129 – 138 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Bradford LD . CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants . Pharmacogenomics3 ( 2 ), 229 – 243 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Zhou S-F , LiuJ-P , ChowbayE . Polymorphism of human cytochrome P450 enzymes and its clinical impact . Drug Metab. Rev.41 ( 2 ), 89 – 295 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• LLerena A , DoradoP , RamírezRet al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans . Pharmacogenomics J.12 ( 2 ), 176 – 183 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Human Cytochrome P450 (CYP) Allele Nomenclature Committee . www.cypalleles.ki.se/cyp2d6.htm .
   Google Scholar
• Sosa-Macías M , ElizondoG , Flores-PérezCet al. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico . J. Clin. Pharmacol.46 ( 5 ), 527 – 536 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Sosa-Macías M , DoradoP , Alanis-BañuelosRE , LLerenaA , Lares-AsseffI . Influence of CYP2D6 deletion, multiplication, -1584C>G, 31G>A and 2988G>A gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos . Pharmacology86 ( 1 ), 30 – 36 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lazalde-Ramos BP , Martinez-FierroMLet al. CYP2D6 gene polymorphism and predicted phenotypes in eight indigenous groups from northwestern Mexico . Pharmacogenomics15 ( 3 ), 339 – 348 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mendoza R , WanYJ , PolandREet al. CYP2D6 polymorphism in a Mexican American population . Clin. Pharmacol. Ther.70 ( 6 ), 552 – 560 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Luo HR , GaedigkA , AloumanisV , WanYJ . Identification of CYP2D6 impaired functional alleles in Mexican Americans . Eur. J. Clin. Pharmacol.61 ( 11 ), 797 – 802 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Casner PR . The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans . J. Clin. Pharmacol.45 ( 11 ), 1230 – 1235 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• López M , GuerreroJ , Jung-CookH , AlonsoME . CYP2D6 genotype and phenotype determination in a Mexican Mestizo population . Eur. J. Clin. Pharmacol.61 ( 10 ), 749 – 754 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Contreras AV , Monge-CazaresT , Alfaro-RuizLet al. Resequencing, haplotype construction and identification of novel variants of CYP2D6 in Mexican Mestizos . Pharmacogenomics12 ( 5 ), 745 – 756 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Dorado P , CáceresM , Pozo-GuisadoE , WongML , LicinioJ , LlerenaA . Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use . Biotechniques39 ( Suppl. 10 ), 571 – 574 ( 2005 ).
   PubMedGoogle Scholar
• Gaedigk A , SimonSD , PearceRE , BradfordLD , KennedyMJ , LeederJS . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype . Clin. Pharmacol. Ther.83 ( 2 ), 234 – 242 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Salazar-Flores J , Torres-ReyesLA , Martínez-CortésGet al. Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico . Genet. Test Mol. Biomarkers16 ( 9 ), 1098 – 1104 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Rangel-Villalobos H , Muñoz-ValleJF , González-MartínA , GorostizaA , MagañaMT , Páez-RiberosLA . Genetic admixture, relatedness, and structure patterns among Mexican populations revealed by the Y-chromosome . Am. J. Phys. Anthropol.135 ( 4 ), 448 – 461 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Nebert DW . Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?Am. J. Hum. Genet.60 ( 2 ), 265 – 271 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Nebert DW , ZhangG , VesellES . From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions . Drug Metab. Rev.40 ( 2 ), 187 – 224 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Peñas-Lledó E , GuillaumeS , NaranjoMEet al. A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances . Pharmacogenomics J. doi:10.1038/tpj.2014.42 ( 2014 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Daly AK . Individualized drug therapy . Curr. Opin. Drug Discov. Devel.10 ( 1 ), 29 – 36 ( 2007 ).
   PubMedGoogle Scholar
• Vivar JC , PemuP , McPhersonR , GhoshS . Redundancy control in pathway databases (ReCiPa): an application for improving gene-set enrichment analysis in Omics studies and ‘Big data’ biology . OMICS17 ( 8 ), 414 – 422 ( 2013 ).
   PubMed Web of Science ®Google Scholar